Nivolumab approved for use in EU as second-line treatment for unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma

Approval was based on Phase 3 ATTRACTION-3 trial showing statistically significant and clinically meaningful improvement in overall survival compared to chemotherapy. The safety profile was also more favourable which is consistent with previous studies in other solid tumours.

Biospace Inc.